Emma Palfreyman, Jenny Morrison, Brett Wilson, Glenda Millard, Yew Wah Liew, Tanya Powley, James Daly
{"title":"在澳大利亚土著人群中,部分D变异具有D异体免疫的风险。","authors":"Emma Palfreyman, Jenny Morrison, Brett Wilson, Glenda Millard, Yew Wah Liew, Tanya Powley, James Daly","doi":"10.1111/vox.70113","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Two prior publications have identified a novel RHD variant in the Australian population with the pattern of single nucleotide variation (SNV) c.186G>T, c.410C>T, c.455A>C, c.602C>G, c.604G>A, c.733G>C, and a deletion or rearrangement with RHCE exon 9. The Australian Red Cross Lifeblood provides testing across Australia, and over a period of 8 years, this same RHD variant has been noted, with some cases presenting with allogeneic anti-D.</p><p><strong>Materials and methods: </strong>Cases with the combination of SNVs were identified with the RHD BeadChip™ panel and massively parallel sequencing, and were collated. Clinical presentation, phenotype and the specificity of any antibodies were also reviewed.</p><p><strong>Results: </strong>Twelve cases of the same pattern of SNV and exon change were identified. There was consistent finding of c.186G>T, c.410C>T, c.455A>C, c.602C>G, c.604G>A and c.733G>C, in association with RHCE replacement of exon 9. All cases except one were phenotypically D-positive. Nine of 12 cases presented with anti-D antibodies, often associated with pregnancy. Where ethnicity was reported, all individuals were of Australian Indigenous ethnicity.</p><p><strong>Conclusion: </strong>This RHD variant is observed to date only in people of Australian Indigenous ethnicity and has clinical relevance. With wider knowledge of the variant, it is anticipated that there will be increased screening in this population, especially in women of childbearing age.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Partial D variant with demonstrated risk of D alloimmunization in the Australian Indigenous population.\",\"authors\":\"Emma Palfreyman, Jenny Morrison, Brett Wilson, Glenda Millard, Yew Wah Liew, Tanya Powley, James Daly\",\"doi\":\"10.1111/vox.70113\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Two prior publications have identified a novel RHD variant in the Australian population with the pattern of single nucleotide variation (SNV) c.186G>T, c.410C>T, c.455A>C, c.602C>G, c.604G>A, c.733G>C, and a deletion or rearrangement with RHCE exon 9. The Australian Red Cross Lifeblood provides testing across Australia, and over a period of 8 years, this same RHD variant has been noted, with some cases presenting with allogeneic anti-D.</p><p><strong>Materials and methods: </strong>Cases with the combination of SNVs were identified with the RHD BeadChip™ panel and massively parallel sequencing, and were collated. Clinical presentation, phenotype and the specificity of any antibodies were also reviewed.</p><p><strong>Results: </strong>Twelve cases of the same pattern of SNV and exon change were identified. There was consistent finding of c.186G>T, c.410C>T, c.455A>C, c.602C>G, c.604G>A and c.733G>C, in association with RHCE replacement of exon 9. All cases except one were phenotypically D-positive. Nine of 12 cases presented with anti-D antibodies, often associated with pregnancy. Where ethnicity was reported, all individuals were of Australian Indigenous ethnicity.</p><p><strong>Conclusion: </strong>This RHD variant is observed to date only in people of Australian Indigenous ethnicity and has clinical relevance. With wider knowledge of the variant, it is anticipated that there will be increased screening in this population, especially in women of childbearing age.</p>\",\"PeriodicalId\":23631,\"journal\":{\"name\":\"Vox Sanguinis\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-09-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vox Sanguinis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/vox.70113\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70113","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的:之前的两篇文章已经在澳大利亚人群中发现了一种新的RHD变异,其模式为单核苷酸变异(SNV) C . 186g >T, C . 410c >T, C . 455a >C, C . 602c >G, C . 604g > a, C . 733g >C,以及RHCE外显子9的缺失或重排。澳大利亚红十字会生命血液在澳大利亚各地提供测试,在8年的时间里,同样的RHD变体已经被注意到,一些病例表现为异体抗d。材料和方法:使用RHD BeadChip™面板和大规模平行测序对合并snv的病例进行鉴定,并进行整理。临床表现,表型和任何抗体的特异性也进行了回顾。结果:共鉴定出12例SNV和外显子变化相同的病例。C . 186g >T、C . 410c >T、C . 455a >C、C . 602c >G、C . 604g >A和C . 733g >C与RHCE替换外显子9有关。除一例外,所有病例均为表型d阳性。12例中有9例出现抗d抗体,通常与妊娠有关。在报告种族的地方,所有个人都是澳大利亚土著民族。结论:迄今为止,这种RHD变异仅在澳大利亚土著人群中观察到,并具有临床相关性。随着对这种变异的了解越来越广泛,预计这一人群,特别是育龄妇女的筛查将会增加。
Partial D variant with demonstrated risk of D alloimmunization in the Australian Indigenous population.
Background and objectives: Two prior publications have identified a novel RHD variant in the Australian population with the pattern of single nucleotide variation (SNV) c.186G>T, c.410C>T, c.455A>C, c.602C>G, c.604G>A, c.733G>C, and a deletion or rearrangement with RHCE exon 9. The Australian Red Cross Lifeblood provides testing across Australia, and over a period of 8 years, this same RHD variant has been noted, with some cases presenting with allogeneic anti-D.
Materials and methods: Cases with the combination of SNVs were identified with the RHD BeadChip™ panel and massively parallel sequencing, and were collated. Clinical presentation, phenotype and the specificity of any antibodies were also reviewed.
Results: Twelve cases of the same pattern of SNV and exon change were identified. There was consistent finding of c.186G>T, c.410C>T, c.455A>C, c.602C>G, c.604G>A and c.733G>C, in association with RHCE replacement of exon 9. All cases except one were phenotypically D-positive. Nine of 12 cases presented with anti-D antibodies, often associated with pregnancy. Where ethnicity was reported, all individuals were of Australian Indigenous ethnicity.
Conclusion: This RHD variant is observed to date only in people of Australian Indigenous ethnicity and has clinical relevance. With wider knowledge of the variant, it is anticipated that there will be increased screening in this population, especially in women of childbearing age.
期刊介绍:
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.